Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

NCT01552447 | Completed

• 1 other identifier: EFVLU001
• Study Type: interventional
• Target: 98
• Locations: 1 country
• Sites: 5

Brief Summary

The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

Conditions

Venous Leg Ulcer

Outcome Measures

Primary Outcomes (1)

• The proportion of wounds achieving 40% closure in patients treated with amniotic membrane vs. standard of care

  4 week

Secondary Outcomes (3)

• The proportion of wounds achieving 40% closure in patients treated with one application of amniotic membrane vs. standard of care

  4 week

• The proportion of wounds achieving 40% closure in patients treated with one application of amniotic membrane vs. 2 applications of amniotic membrane

  4 week

• The proportion of wounds achieving 40% closure in patients treated with two applications of amniotic membrane vs. standard of care

  4 week

Study Arms (3)

1 application of EpiFix

OTHER

1 x dehydrated human amnion/chorion membrane

Other: EpiFix; Other: Compression Therapy

2 applications of EpiFix

OTHER

2 x dehydrated human amnion/chorion membrane

Other: EpiFix; Other: Compression Therapy

Standard of care

OTHER

Compression bandaging

Other: Compression Therapy

Interventions

EpiFix OTHER

Dehydrated placental tissue

1 application of EpiFix; 2 applications of EpiFix

Compression Therapy OTHER

Compression bandaging

1 application of EpiFix; 2 applications of EpiFix; Standard of care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 18 years old
• Ankle Brachial Pressure Index (ABI) \> 0.75
• Presence of a venous leg ulcer extending through the full thickness of the skin but not down to muscle, tendon or bone
• Study ulcer has been present for at least one month prior to the initial screening visit, and is excluded if it has undergone 12 months of continuous high strength compression therapy over its duration
• Study ulcer is a minimum of 2 cm2 and a maximum of 20 cm2 at the Randomization visit
• The target ulcer has been treated with compression therapy for at least 14 days prior to randomization
• Ulcer has a clean, granulating base with minimal adherent slough at the Randomization visit
• Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
• Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen
• Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken

You may not qualify if:

• Study ulcer(s) deemed by the investigator to be caused by a medical condition other than venous insufficiency
• Study ulcer exhibits clinical signs and symptoms of infection.
• Non-mobile i.e. not ambulatory, or bed ridden
• Study ulcer, in the opinion of the investigator, is suspicious for cancer should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
• Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
• Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding Screening
• History of radiation at the ulcer site
• Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
• Study ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days
• Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the course of the trial.
• Patients who are unable to understand the aims and objectives of the trial
• Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment
• NYHA Class III and IV congestive heart failure (CHF), as defined by the following criteria: Class III: Symptoms with moderate exertion; Class IV: Symptoms at rest
• Ulcers on the dorsum of the foot or with more than 50% of the ulcer below the malleolus are excluded.
• Pregnant or breast feeding

Sponsors & Collaborators

• MiMedx Group, Inc.: lead

Study Sites (5)

Eric J. Lullove DPM

Boca Raton, Florida, 33433, United States

Location

MetroWest Medical Center

Framingham, Massachusetts, United States

Location

St. Johns Wound Center

Tulsa, Oklahoma, United States

Location

St. Vincent's Health Center

Erie, Pennsylvania, 16502, United States

Location

Armstrong County Memorial Hospital

Kittanning, Pennsylvania, 16201, United States

Location

MeSH Terms

Conditions

Varicose Ulcer

Condition Hierarchy (Ancestors)

Varicose Veins; Vascular Diseases; Cardiovascular Diseases; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Thomas E Serena, MD

  Penn North Centers for Advanced Wound Care

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2012
• First Posted: March 13, 2012
• Study Start: March 1, 2012
• Primary Completion: May 1, 2014
• Study Completion: May 1, 2014
• Last Updated: March 16, 2016

Record last verified: 2016-03

Locations

US (5)